Cidara Therapeutics Inc (CDTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cidara Therapeutics Inc (CDTX) has a cash flow conversion efficiency ratio of -0.096x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.62 Million) by net assets ($422.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cidara Therapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Cidara Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Cidara Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cidara Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cidara Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Gold Inc
TO:NGD
|
0.175x |
|
Svenska Cellulosa Aktiebolaget SCA (publ)
ST:SCA-B
|
0.010x |
|
Molina Healthcare Inc
NYSE:MOH
|
-0.073x |
|
Samsung Engineering
KO:028050
|
-0.059x |
|
RATIONAL UN.ADR 1/ 1/20
F:RAA1
|
0.096x |
|
STAG Industrial Inc
NYSE:STAG
|
0.041x |
|
Sonic Healthcare Ltd
AU:SHL
|
0.078x |
|
SODEXO S.A. ADR/ 1/5 EO 4
F:SJ70
|
N/A |
Annual Cash Flow Conversion Efficiency for Cidara Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Cidara Therapeutics Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see CDTX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $163.31 Million | $-176.53 Million | -1.081x | -139.56% |
| 2023-12-31 | $-8.21 Million | $-22.43 Million | 2.732x | +38.55% |
| 2022-12-31 | $-14.44 Million | $-28.47 Million | 1.972x | +268.61% |
| 2021-12-31 | $21.57 Million | $-25.23 Million | -1.170x | +76.97% |
| 2020-12-31 | $10.71 Million | $-54.41 Million | -5.078x | -573.37% |
| 2019-12-31 | $37.84 Million | $-28.53 Million | -0.754x | +21.35% |
| 2018-12-31 | $59.14 Million | $-56.70 Million | -0.959x | -14.78% |
| 2017-12-31 | $59.74 Million | $-49.91 Million | -0.835x | -85.22% |
| 2016-12-31 | $88.18 Million | $-39.77 Million | -0.451x | -80.54% |
| 2015-12-31 | $103.91 Million | $-25.96 Million | -0.250x | +31.62% |
| 2014-12-31 | $21.10 Million | $-7.71 Million | -0.365x | -148.74% |
| 2013-12-31 | $-1.40 Million | $-1.05 Million | 0.750x | -- |
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are funga… Read more